Meanwhile, targeting environmental cells in a leukemia niche such as a macrophage/monocyte is a promising strategy due to its prevalence in various kinds of tumors.[7] CD64 expressions in leukemia and tumor macrophages has been reported,[15, 37] which supports clinical relevance of CD64‐targeting. Here, FCGR1A is linked to neoplasm.